CNSYCerenome Inc. Common Stock

3.070USD+2.33%Mkt Cap: 23.30M $P/E: 1.05

Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obi…

Key Statistics

Company
Market Cap23.30M $
Enterprise Value10.94M $
Revenue (TTM)5.18M $
Gross Profit-4.31M $
Net Income (TTM)-22.39M $
Revenue/Share1.120 USD
Last Price3.070 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees28
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN
Valuation
P/E (Trailing)1.05
P/E (Forward)-1.25
PEG2.45
EV/EBITDA-0.59
EV/Revenue2.11
P/S4.39
P/B4.17
EPS (TTM)2.76
EPS (Forward)-2.40
52W Range
2.9001% of range23.50
52W High23.50 USD
52W Low2.900 USD
Profitability
Gross Margin-83.09%
Oper. Margin-692.51%
EBITDA Margin0.00%
Profit Margin-230.24%
ROE-560.21%
ROA-137.13%
Growth
Revenue Growth-2.90%
Earnings Growth
Cash Flow & Leverage
Operating CF-20.77M $
CapEx (TTM)67.00K $
FCF Margin-291.55%
FCF Yield-64.84%
Net Debt-14.39M $
Net Debt/EBITDA0.78
Balance Sheet
Debt/Equity0.21
Current Ratio2.27
Quick Ratio2.07
Book Value/Sh0.7200 USD
Cash/Share2.196 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay Date
Splits
Last Split1:25
Split DateApr 2, 2026
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)36.00 USD
Upside (mean)+1072.6%
Target Range12.00 USD57.00 USD
$12.00+1072.6% to mean$57.00
# Analysts4
Ownership
Shares Out.7.59M
Float6.46M
Insiders1.84%
Institutions16.88%
Short Interest
Short Ratio3.0d
Short % Float10.35%
Short % Out.10.30%
Shares Short709.38K
Short (prev mo.)1.12M
Technical
SMA 503.982 (-22.9%)
SMA 2007.622 (-59.7%)
Beta1.42
S&P 52W Chg18.16%
Avg Vol (30d)106.94K
Avg Vol (10d)88.42K
Technical Indicators
RSI (14)30.3
MACD-0.2431
MACD Signal-0.1877
MACD Hist.-0.0554
BB Upper4.219 USD
BB Middle3.638 USD
BB Lower3.057 USD
BB Width31.92%
ATR (14)0.2875 USD
Vol Ratio (20d)1.30x